This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McLaughlin, J Articles by Witte, O N Search for Related Content PubMed PubMed Citation Articles by McLaughlin, J Articles by Witte, O N

 Previous Article  |  Next Article 

Mol Cell Biol. 1989 May; 9(5): 1866-1874

Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.

Department of Microbiology, University of California, Los Angeles 90024-1570.

ABSTRACT

The Philadelphia chromosome (t9:22;q34:q11) is found in more than 90% of patients with chronic myelogenous leukemia, in 10 to 20% of patients with acute lymphocytic leukemia, and in 1 to 2% of patients with acute myelogenous leukemia. Alternative chimeric oncogenes are formed by splicing different sets of BCR gene exons on chromosome 22 across the translocation breakpoint to a common set of ABL oncogene sequences on chromosome 9. This results in an 8.7-kilobase mRNA that encodes the P210 BCR-ABL gene product commonly found in patients with chronic myelogenous leukemia or a 7.0-kilobase mRNA that produces the P185 BCR-ABL gene product found in most Philadelphia chromosome-positive patients with acute lymphocytic leukemia. To compare the efficiency of growth stimulation by these two proteins, we derived cDNA clones for each with identical 5' and 3' untranslated regions and expressed them from retrovirus vectors. Matched stocks were compared for potency to transform immature B-lymphoid lineage precursors. The growth-stimulating effects of P185 for this cell type were found to be significantly greater than those of P210. Structural changes in BCR may regulate the effectiveness of the ABL tyrosine kinase function, as monitored by lymphocyte growth response. Changes in mitogenic potency may help to explain the more acute leukemic presentation usually associated with expression of the P185 BCR-ABL oncogene.

This article has been cited by other articles:

• McLaughlin, J., Cheng, D., Singer, O., Lukacs, R. U., Radu, C. G., Verma, I. M., Witte, O. N. (2007). Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics. Proc. Natl. Acad. Sci. USA 104: 20501-20506 [Abstract] [Full Text]  
• Skaggs, B. J., Gorre, M. E., Ryvkin, A., Burgess, M. R., Xie, Y., Han, Y., Komisopoulou, E., Brown, L. M., Loo, J. A., Landaw, E. M., Sawyers, C. L., Graeber, T. G. (2006). Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc. Natl. Acad. Sci. USA 103: 19466-19471 [Abstract] [Full Text]  
• Million, R. P., Harakawa, N., Roumiantsev, S., Varticovski, L., Van Etten, R. A. (2004). A Direct Binding Site for Grb2 Contributes to Transformation and Leukemogenesis by the Tel-Abl (ETV6-Abl) Tyrosine Kinase. Mol. Cell. Biol. 24: 4685-4695 [Abstract] [Full Text]  
• Wassmann, B., Pfeifer, H., Scheuring, U. J., Binckebanck, A., Gokbuget, N., Atta, J., Bruck, P., Rieder, H., Schoch, C., Leimer, L., Schwerdtfeger, R., Ehninger, G., Lipp, T., Perz, J., Stelljes, M., Gschaidmeier, H., Hoelzer, D., Ottmann, O. G. (2004). Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. Blood 103: 1495-1498 [Abstract] [Full Text]  
• Smith, K. S., Rhee, J. W., Cleary, M. L. (2002). Transformation of Bone Marrow B-Cell Progenitors by E2A-HLF Requires Coexpression of BCL-2. Mol. Cell. Biol. 22: 7678-7687 [Abstract] [Full Text]  
• Jena, N., Deng, M., Sicinska, E., Sicinski, P., Daley, G. Q. (2002). Critical Role for Cyclin D2 in BCR/ABL-induced Proliferation of Hematopoietic Cells. Cancer Res. 62: 535-541 [Abstract] [Full Text]  
• Mainville, C. A., Parmar, K., Unnikrishnan, I., Gong, L., Raffel, G. D., Rosenberg, N. (2001). Temperature-Sensitive Transformation by an Abelson Virus Mutant Encoding an Altered SH2 Domain. J. Virol. 75: 1816-1823 [Abstract] [Full Text]  
• Roumiantsev, S., de Aos, I. E., Varticovski, L., Ilaria, R. L., Van Etten, R. A. (2001). The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood 97: 4-13 [Abstract] [Full Text]  
• Cobaleda, C., Sanchez-Garcia, I. (2000). In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment. Blood 95: 731-737 [Abstract] [Full Text]  
• Li, S., Ilaria, R. L. Jr., Million, R. P., Daley, G. Q., Van Etten, R. A. (1999). The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia-like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity. J. Exp. Med. 189: 1399-1412 [Abstract] [Full Text]  
• Till, J. H., Chan, P. M., Miller, W. T. (1999). Engineering the Substrate Specificity of the Abl Tyrosine Kinase. J. Biol. Chem. 274: 4995-5003 [Abstract] [Full Text]  
• Shi, C.-S., Tuscano, J. M., Witte, O. N., Kehrl, J. H. (1999). GCKR Links the Bcr-Abl Oncogene and Ras to the Stress-Activated Protein Kinase Pathway. Blood 93: 1338-1345 [Abstract] [Full Text]  
• Zhang, X., Ren, R. (1998). Bcr-Abl Efficiently Induces a Myeloproliferative Disease and Production of Excess Interleukin-3 and Granulocyte-Macrophage Colony-Stimulating Factor in Mice: A Novel Model for Chronic Myelogenous Leukemia. Blood 92: 3829-3840 [Abstract] [Full Text]  
• Dai, Z., Quackenbush, R. C., Courtney, K. D., Grove, M., Cortez, D., Reuther, G. W., Pendergast, A. M. (1998). Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. Genes Dev. 12: 1415-1424 [Abstract] [Full Text]  
• Reuther, J. Y., Reuther, G. W., Cortez, D., Pendergast, A. M., Baldwin Jr., A. S. (1998). A requirement for NF-kappa B activation in Bcr-Abl-mediated transformation. Genes Dev. 12: 968-981 [Abstract] [Full Text]  
• Satterthwaite, A. B., Cheroutre, H., Khan, W. N., Sideras, P., Witte, O. N. (1997). Btk dosage determines sensitivity to B cell antigen receptor cross-linking. Proc. Natl. Acad. Sci. USA 94: 13152-13157 [Abstract] [Full Text]  
• Castellanos, A., Pintado, B., Weruaga, E., Arevalo, R., Lopez, A., Orfao, A., Sanchez-Garcia, I. (1997). A BCR-ABLp190 Fusion Gene Made by Homologous Recombination Causes B-Cell Acute Lymphoblastic Leukemias in Chimeric Mice With Independence of the Endogenous bcr Product. Blood 90: 2168-2174 [Abstract] [Full Text]  
• Lugo, T., Pendergast, A., Muller, A., Witte, O. (1990). Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079-1082 [Abstract]  
• Lim, Y.-M., Wong, S., Lau, G., Witte, O. N., Colicelli, J. (2000). BCR/ABL inhibition by an escort/phosphatase fusion protein. Proc. Natl. Acad. Sci. USA 97: 12233-12238 [Abstract] [Full Text]